Boston Pharmaceuticals Licenses Potential NASH Treatment from Novartis
BioSpace
AUGUST 31, 2020
Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21.
BioSpace
AUGUST 31, 2020
Boston Pharmaceuticals licensed the drug candidate BOS-580, an injectable, genetically engineered variant of human FGF21.
The Pharma Data
NOVEMBER 4, 2020
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 Juyou Bio-Technology Co.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 6, 2020
The company is trying to repurpose the drug used in rare inflammatory diseases such as juvenile arthritis for COVID-19, to see if it could relieve the extreme immune reaction that can prove fatal after infection with coronavirus. An interim analysis will be submitted to a peer-reviewed journal in the coming weeks.
The Pharma Data
JANUARY 17, 2021
a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio. . These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor. RENSSELAER, N.Y.,
Drug Discovery World
JULY 10, 2023
This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. As a result, model generation is an attractive option often considered in parallel.
pharmaphorum
MAY 7, 2021
CRISPR’s deal with Nkarta aims to create genetically engineered NK cells, which are harvested and used to create a bank of “off the shelf” cells that can administered to patients like a drug. Nkarta also gets a license to CRISPR gene editing to an unlimited number of its own NK cell therapy products.
The Pharma Data
APRIL 27, 2023
It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.
Let's personalize your content